Leishmania donovani bodies in bone marrow by Ali, Natasha & Hussain, Shabneez
eCommons@AKU
Department of Pathology and Laboratory Medicine Medical College, Pakistan
October 2014
Leishmania donovani bodies in bone marrow
Natasha Ali
Aga Khan University, natasha.ali@aku.edu
Shabneez Hussain
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_pathol_microbiol
Part of the Hematology Commons, Microbiology Commons, Oncology Commons, and the
Pathology Commons
Recommended Citation
Ali, N., Hussain, S. (2014). Leishmania donovani bodies in bone marrow. Clinical Case Reports, 2(5), 238-239.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_pathol_microbiol/891
CLINICAL IMAGE
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Key Clinical Message
We report a case of a 5-year-old female, resident of Afghanistan, who presented
with fever and massive splenomegaly. Bone marrow revealed Leishmania dono-
vani bodies (LD bodies) in macrophages characterized by a kinetoplast and
characteristic double dot appearance. She was diagnosed as visceral leishmania-
sis which is transmitted by sandflies (Phlebotomus).
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Dear Editor,
We report a case of a 5-year-old female, resident of
Afghanistan who was evaluated for high grade, intermit-
tent fevers over the last 5 months. On examination, she
had pallor and massive splenomegaly. Complete blood
count results showed hemoglobin: 7.6 g/dL, white blood
cell count: 2.3 9 109/L, and platelet count: 70 9 109/L.
The peripheral blood smear revealed anisocytosis, poly-
chromasia and pancytopenia. Subsequently, bone marrow
procedure was performed as a part of workup for evalua-
tion of fever and splenomegaly. Bone marrow aspirate
showed Leishmania donovani bodies (LD bodies) in mac-
rophages characterized by a kinetoplast and characteristic
double dot appearance (Fig. 1A and B). Normal hemato-
poiesis was noted. A diagnosis visceral leishmaniasis was
made.
Leishmaniasis is caused by a protozoan, Leishmania, of
which more than 20 species have been identified. Leish-
mania is transmitted by sandflies (Phlebotomus). It has
an estimated annual incidence of 2 million cases in 98
countries [1] It manifests itself as three main clinical
(A) (B)
Figure 1. (A and B) macrophage infested with intracellular Leishmania donovani bodies (arrows) characterized by a kinetoplast and characteristic
double dot appearance (Leishman stain) (1009 magnification).
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syndromes: cutaneous, mucocutaneous, and visceral dis-
ease. Visceral leishmaniasis (kala-azar) occurs due to
infestation of the macrophages in the reticuloendothelial
system resulting in hepatosplenomegaly, while involve-
ment of bone marrow leads to suppression of hemopoie-
sis. In countries like India, Pakistan, and China, visceral
Leishmaniasis is caused by Leishmania donovani. In the
Mediterranean region, Leishmania infantum is the culprit
and Leishmania tropica is reported to be the causative
agent in the Middle East [2]. Management includes
amphotericin B, sodium stiboguconate or miltefosine [3–
5].
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